Create a concise, evidence-based PowerPoint on Hepatic Encephalopathy (HE) for gastroenterology residency, ward rounds and viva examinations. Use current EASL/AASLD guidelines and high-quality literature. Include the following high-yield clinical information: Definition & classification: Type A (acute liver failure), B (portosystemic shunting), C (cirrhosis); covert vs overt HE; episodic, recurrent and persistent HE. Diagnosis & named criteria: West Haven grading (grades 0–IV), clinical features of each grade, asterixis, and Glasgow Coma Scale for severe cases. Explain that HE is a clinical diagnosis of exclusion with no single confirmatory test. Cover ammonia limitations, differential diagnoses, investigations and when brain CT/MRI is indicated. Precipitating factors: GI bleeding, infections/SBP, constipation, dehydration, AKI, electrolyte disturbances, sedatives/opioids, medication nonadherence and TIPS. Include a checklist for identifying and correcting them. Acute management with adult doses: Stabilize ABCs, assess glucose and protect the airway; ICU assessment for grade III–IV HE or threatened airway. Lactulose: 25 mL orally/NG every 1–2 hours initially until at least two soft stools, then titrate to 2–3 soft bowel movements daily; include rectal administration when necessary. Rifaximin: 550 mg orally twice daily, particularly as adjunctive secondary prevention for recurrent HE. Treat precipitating factors and monitor hydration, electrolytes and renal function. Explain lactulose overuse and complications. Nutrition: avoid protein restriction; target approximately 1.2–1.5 g protein/kg/day and 35 kcal/kg/day in cirrhosis, individualized to the patient. Secondary prevention: Lactulose after the first overt episode; add rifaximin after recurrent HE, especially recurrence despite lactulose. Include adherence, caregiver education and transplant evaluation for recurrent/persistent HE. Special scenarios: HE with variceal bleeding, post-TIPS HE, covert HE, refractory HE and HE in acute liver failure. Monitoring & prognosis: Clinical response, stool targets, precipitant resolution, recurrence risk, discharge criteria and transplant referral. Practical clinical algorithm: Recognition → West Haven grading → airway assessment → investigations and precipitant search → treatment → reassessment and disposition. Viva preparation: Include 3 short clinical cases with answers and 10 high-yield consultant questions. Use 10–12 slides with concise bullets, a West Haven table, a medication-dose table, a management flowchart and a final clinical pearls slide. Cite authoritative guidelines and landmark studies. Distinguish evidence-based recommendations from uncertain therapies. Do not invent doses or references. Verify doses against current guidelines and local protocols.
Create a concise, evidence-based PowerPoint on Hepatic Encephalopathy (HE) for gastroenterology residency, ward rounds and viva examinations. Use current EASL/AASLD guidelines and high-quality literature. Include the following high-yield clinical information:
Definition & classification: Type A (acute liver failure), B (portosystemic shunting), C (cirrhosis); covert vs overt HE; episodic, recurrent and persistent HE.
Diagnosis & named criteria: West Haven grading (grades 0–IV), clinical features of each grade, asterixis, and Glasgow Coma Scale for severe cases. Explain that HE is a clinical diagnosis of exclusion with no single confirmatory test. Cover ammonia limitations, differential diagnoses, investigations and when brain CT/MRI is indicated.
Precipitating factors: GI bleeding, infections/SBP, constipation, dehydration, AKI, electrolyte disturbances, sedatives/opioids, medication nonadherence and TIPS. Include a checklist for identifying and correcting them.
Acute management with adult doses:
Stabilize ABCs, assess glucose and protect the airway; ICU assessment for grade III–IV HE or threatened airway.
Lactulose: 25 mL orally/NG every 1–2 hours initially until at least two soft stools, then titrate to 2–3 soft bowel movements daily; include rectal administration when necessary.
Rifaximin: 550 mg orally twice daily, particularly as adjunctive secondary prevention for recurrent HE.
Treat precipitating factors and monitor hydration, electrolytes and renal function. Explain lactulose overuse and complications.
Nutrition: avoid protein restriction; target approximately 1.2–1.5 g protein/kg/day and 35 kcal/kg/day in cirrhosis, individualized to the patient.
Secondary prevention: Lactulose after the first overt episode; add rifaximin after recurrent HE, especially recurrence despite lactulose. Include adherence, caregiver education and transplant evaluation for recurrent/persistent HE.
Special scenarios: HE with variceal bleeding, post-TIPS HE, covert HE, refractory HE and HE in acute liver failure.
Monitoring & prognosis: Clinical response, stool targets, precipitant resolution, recurrence risk, discharge criteria and transplant referral.
Practical clinical algorithm: Recognition → West Haven grading → airway assessment → investigations and precipitant search → treatment → reassessment and disposition.
Viva preparation: Include 3 short clinical cases with answers and 10 high-yield consultant questions.
Use 10–12 slides with concise bullets, a West Haven table, a medication-dose table, a management flowchart and a final clinical pearls slide. Cite authoritative guidelines and landmark studies. Distinguish evidence-based recommendations from uncertain therapies. Do not invent doses or references. Verify doses against current guidelines and local protocols.
Created using ChatSlide
This guide focuses on recognizing and classifying hepatic encephalopathy, detailing types A, B, and C, and utilizing West Haven grades for diagnosis. It emphasizes treating episodes by stabilizing patients, correcting precipitants, and administering lactulose and rifaximin while monitoring nutrition and transplant needs. Additionally, it provides an algorithm for ward rounds, addressing complications like bleeding and acute liver failure, and includes practical case studies and viva questions...